Skip to main content
. Author manuscript; available in PMC: 2022 Apr 10.
Published in final edited form as: Sci Transl Med. 2021 Jan 20;13(577):eaba7401. doi: 10.1126/scitranslmed.aba7401

Figure 7. Combined therapy consisting of LY2606368 and cisplatin significantly improves survival in G3 MB but to a lesser extent than cyclophosphamide.

Figure 7.

(A) Preclinical mouse treatment protocol for mice with orthotopic G3-II for data shown in B. (B) Survival curves are shown for the G3-II MB models indicated. Log-rank tests compared the combination-treated group with each other group: p < 0.016667, *; P < 0.005, **; P < 0.001, ***; P < 0.0001, ****; not significant (ns), P ≧ 0.01667. The number of mice per group (n) is shown. (C) Treatment protocol for mice with SU-MB002 or D425 G3 MBs for data shown in D. (D) Immunohistochemistry (IHC) for phospho-CHK1 Ser345, γH2AX, and cleaved caspase 3 was performed and positive nuclei were quantified from 4 sections from 4–5 mice/group (mean ± SEM) with colors corresponding to (C). Significant differences were determined using a one-way ANOVA with Tukey’s multiple comparisons test with p values indicated in (D).